A Phase 1/2 interventional study of Linifanib and BIBW2992 in Endometriosis, Endometriosis Ovary and Endometriosis Externa, sponsored by BioGene Pharmaceutical Ltd.. Withdrawn at 1 site in Switzerland. Open to female participants aged 19 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-10-29.
Sponsored by BioGene Pharmaceutical Ltd. · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Endometriosis with a site in Switzerland — 8 open to participants now, 8 under way, 1 of them phase 3. Endometriosis · Switzerland.
Among the 21 studies in Endometriosis with a site in Switzerland, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2021, is one of 2 in phase 1/2, and was the 4th registered.
922 studies on the registry are indexed under Endometriosis; 268 are open to participants now.
Browse Endometriosis studies →8 of the 21 studies in Endometriosis with a site in Switzerland are open now. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–40 · Women only
University Hospital, Geneva · Sites in Switzerland
Ages 18+ · Women only · Healthy volunteers
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+ · Women only
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+ · Women only
ZIWIG · Sites in Switzerland, Belgium, France
Ages 10–19 · Women only
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 179 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 125 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 19 Years to 60 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 1 · Phase 4 1
First in 2010; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 91 across the 12 interventional studies, 80 across the 9 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 21 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with BioGene Pharmaceutical Ltd. as lead sponsor.
BioGene Pharmaceutical Ltd. has 1 study filed under Endometriosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Endometriosis with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173127University Hospital, GenevaThe Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters | 2026-12-30 |
| NCT06821217Insel Gruppe AG, University Hospital BernThe Effect of an App-based Intervention on Quality of Life in Patients With Endometriosis. | 2026-12-31 |
| NCT07711743Insel Gruppe AG, University Hospital BernHistological Assessment of Tissue Penetration Depth of Argon Beam Coagulation in Ovarian Endometriomas | 2027-07-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Endometriosis with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background:
Endometriosis is a chronic gynecological disease with the growth of endometrial tissue outside the endometrium. In all its properties, this tissue is similar to the mucous membrane of the uterus.
Types of endometriosis:
Endometriosis is divided into genital and extragenital. Genital endometriosis is internal and external. When the inner is affected by the uterus, with the external - the ovaries, tubes, vagina and external genital organs are affected. Extragenital endometriosis can affect various organs of the abdominal cavity.
Drug treatment does not show high effectiveness. Surgery / laparoscopic is currently considered the gold standard treatment for this problem, including infertility treatment.
The purpose of our studies is to achieve substantial results with respect to tolerability, safety and clinical efficacy of vaginal suppository ELTA for treatment of the endometriosis.
Methods:
Phase I clinical trial to be conducted at Cancer Center to hold under the aegis UniversitätsSpital Zürich from May 2018 to September 2018.
Ninety-four patients with the form of genital endometriosis will take part in the studies. The study was approved by the Ethics Committee at the Cancer Institute no C99884.01FH339
The composition of the endometrium includes epithelial cell layers lining the uterine cavity, and deeper stroma, including the secretory glands. Each layer is characterized by the presence of a large number of blood vessels, through which a sufficient amount of blood is delivered. A large number of these vessels and arteries go to the surface layers due to myometrium and form a capillary network in the stroma.
In the vaginal suppositories, the investigators applied minimally therapeutic doses of inhibitors of neoangiogenesis, as well as other components that caused the pathological growth of the endometrium.
Anti-angiogenic therapy - inhibition of proliferative processes in the vascular wall of capillaries and small vessels in the endometrium, is the determining factor of the therapeutic effect of endometriosis when treated with vaginal suppositories.
The composition of the suppository:
(the composition and amount of excipients are maximally optimal for bioavailability of drugs from suppositories, taking into account the pharmacokinetics, pharmacodynamics and synergy of active drugs) This therapy has a slight teratogenic effect, which should be taken into account when planning pregnancy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Daily single administration of vaginal suppository in diagnosed endometriosis. Duration of admission-five days, two days-off. The total duration of treatment is 6 weeks. General course -30 vaginal suppositories ELTA The composition of the suppository: * Axitinib (inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit) in a minimally sufficient therapeutic dose * Afatinib (BIBW2992) EGFR / HER2 including EGFR (wt), EGFR (L858R), EGFR (L858R / T790M) and HER2 inhibitor - minimally sufficient therapeutic dose * Linifanib (ABT-869) ATP-competitive VEGFR / PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ - minimally sufficient therapeutic dose
Biological: Linifanib · Drug: BIBW2992 · Drug: Axitinib
in a minimally sufficient therapeutic dose
Also known as: ABT869
in a minimally sufficient therapeutic dose
Also known as: Afatinib, Giotrif
in a minimally sufficient therapeutic dose
Also known as: AG013736;, Inlyta
Local tolerability of the vaginal suppository ELTA defined as a cumulative sum of clinical signs for each patient
Local tolerability of the vaginal suppositories ELTA will be defined as a cumulative sum score of the solicited local /vaginal (consisting of subjectively experienced symptoms rated by the patient: burning, itching, bleeding, pain, dryness and objectively documented findings rated by the physician: redness, petechial bleeding, dryness, swelling) for each patient after every weeks of application (scored from 0 \[none/normal\] to 5 \[severe\]) Weekly visit of patients every seventh day from the beginning of treatment. SCALE EVALUATION EVENTS * burning - 2 points, * dryness - 1 point, * painful symptom- 3 points, * itching - 1 point, * bleeding - 5 points, If there is bleeding or the development of edema - the study for the patient will be stopped.
Time frame: 6 weeks
Subjective symptoms (local tolerability)
Each of the subjective symptoms (scored from 0 \[none/normal\] to 5 \[severe\]) from the first visit (after the first application)/ A detailed description of the symptoms in each visit (with endoscopic photofixation of the endometriosis surface)
Time frame: 7 weeks
Objective findings
Each of the objective symptoms (scored from 0 \[none/normal\] to 3 \[severe\]) from the first visit (after the first application). * dryness, itching, hyperemia of the perineum - 1 point, * pain syndrome with itching / dryness or without - 2 points, * bleeding with pain syndrome (or other symptoms / without them - 3 points, A detailed description of the symptoms in each visit (with endoscopic photofixation of the endometriosis surface)
Time frame: 7 weeks
Global judgement of tolerability
Global judgement of tolerability by investigator and patients. The scores of the Clinical Global Impression (CGI) Scale.
Time frame: 4 weeks
Safety evaluation of therapy
Safety evaluation of therapy. Drugs safety will be evaluated by assessment of adverse events ( ADRs).
Time frame: 15 weeks
Serious Adverse Event.
Occurrence of AE / SAE / ADE / SADE. Characteristics of occured AE / SAE / ADE / SADE
Time frame: up to 15 weeks
Change in pH-value from vaginal smear
pH-value from vaginal smear at every visit for each patient after the 3rd and 6th week of application of suppositories.
Time frame: up to 6 weeks
Change in Vaginal flora
Vaginal flora (Lactobacillus spp., Atopobium vaginae and Gardnerella vaginalis) on the first day of intake (before using the first suppository) and on the day of termination of therapy
Time frame: up to 15 weeks
Other signs of assessing the hip therapy
Mandatory Clinical blood test for each patient after the 3rd and 6th week of application of suppositories. A control blood test on the first day of the 15th week after the start of the first suppository
Time frame: up to 15 weeks
Start is estimated for Oct 2021; primary completion for Oct 2021, 0 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Afatinib